| Sanofi, owner of Genzyme, axes CEO; Effect on Cambridge unit, a key operation, is unclear
The Boston Globe, October 30, 2014 Thursday
Fired: CEO Christopher Viehbacher Sanofi SA's sudden decision Wednesday to fire chief executive Christopher A. Viehbacher sent the company's stock tumbling as the impact on its US subsidiary, Genzyme, remained unclear. Sanofi bought the Cambridge biotech Genzyme Corp. in 2011, and Genzyme, which makes treatments for rare genetic diseases, has been a major money maker and one of the fastest growing units for the French company. Viehbacher, who helped engineer the takeover of Genzyme, even...